CN113662192A - Anti-helicobacter pylori instant lactic acid bacteria agent and preparation method and application thereof - Google Patents
Anti-helicobacter pylori instant lactic acid bacteria agent and preparation method and application thereof Download PDFInfo
- Publication number
- CN113662192A CN113662192A CN202110880879.3A CN202110880879A CN113662192A CN 113662192 A CN113662192 A CN 113662192A CN 202110880879 A CN202110880879 A CN 202110880879A CN 113662192 A CN113662192 A CN 113662192A
- Authority
- CN
- China
- Prior art keywords
- powder
- helicobacter pylori
- lactic acid
- acid bacteria
- lactobacillus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 title claims abstract description 84
- 241000894006 Bacteria Species 0.000 title claims abstract description 59
- 229940037467 helicobacter pylori Drugs 0.000 title claims abstract description 55
- 239000004310 lactic acid Substances 0.000 title claims abstract description 42
- 235000014655 lactic acid Nutrition 0.000 title claims abstract description 42
- 239000003795 chemical substances by application Substances 0.000 title claims abstract description 41
- 238000002360 preparation method Methods 0.000 title claims abstract description 23
- 239000000843 powder Substances 0.000 claims abstract description 74
- 241000218588 Lactobacillus rhamnosus Species 0.000 claims abstract description 22
- 240000006024 Lactobacillus plantarum Species 0.000 claims abstract description 20
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims abstract description 20
- 229940072205 lactobacillus plantarum Drugs 0.000 claims abstract description 20
- 241000186315 Lactobacillus paracasei N1115 Species 0.000 claims abstract description 19
- 241001134770 Bifidobacterium animalis Species 0.000 claims abstract description 18
- 229940118852 bifidobacterium animalis Drugs 0.000 claims abstract description 18
- 238000002156 mixing Methods 0.000 claims abstract description 15
- 235000013305 food Nutrition 0.000 claims abstract description 10
- 229920002774 Maltodextrin Polymers 0.000 claims abstract description 5
- 239000005913 Maltodextrin Substances 0.000 claims abstract description 5
- 229940035034 maltodextrin Drugs 0.000 claims abstract description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 5
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 claims abstract description 4
- 229940107187 fructooligosaccharide Drugs 0.000 claims abstract description 4
- 239000000832 lactitol Substances 0.000 claims abstract description 4
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 claims abstract description 4
- 229960003451 lactitol Drugs 0.000 claims abstract description 4
- 235000010448 lactitol Nutrition 0.000 claims abstract description 4
- 230000036541 health Effects 0.000 claims abstract description 3
- 230000001580 bacterial effect Effects 0.000 claims description 21
- 239000002994 raw material Substances 0.000 claims description 20
- 235000013399 edible fruits Nutrition 0.000 claims description 18
- 239000000796 flavoring agent Substances 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- 235000019634 flavors Nutrition 0.000 claims description 7
- 238000007873 sieving Methods 0.000 claims description 7
- 230000021164 cell adhesion Effects 0.000 abstract description 7
- 210000002490 intestinal epithelial cell Anatomy 0.000 abstract description 7
- 230000003115 biocidal effect Effects 0.000 abstract description 6
- 239000012530 fluid Substances 0.000 abstract description 6
- 230000002496 gastric effect Effects 0.000 abstract description 5
- 206010067484 Adverse reaction Diseases 0.000 abstract description 4
- 230000006838 adverse reaction Effects 0.000 abstract description 4
- 241001465754 Metazoa Species 0.000 abstract description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 16
- 239000003826 tablet Substances 0.000 description 16
- 230000000694 effects Effects 0.000 description 15
- 241000590002 Helicobacter pylori Species 0.000 description 13
- 230000000968 intestinal effect Effects 0.000 description 11
- 235000020192 probiotic milk Nutrition 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 241000186660 Lactobacillus Species 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 230000000052 comparative effect Effects 0.000 description 8
- 229940039696 lactobacillus Drugs 0.000 description 8
- 239000006041 probiotic Substances 0.000 description 8
- 235000018291 probiotics Nutrition 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 230000004083 survival effect Effects 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 210000004051 gastric juice Anatomy 0.000 description 7
- 239000001963 growth medium Substances 0.000 description 7
- 210000001035 gastrointestinal tract Anatomy 0.000 description 6
- 230000006872 improvement Effects 0.000 description 6
- 210000000214 mouth Anatomy 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 5
- 238000011049 filling Methods 0.000 description 5
- 235000015203 fruit juice Nutrition 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 229940088710 antibiotic agent Drugs 0.000 description 4
- 238000000227 grinding Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000009629 microbiological culture Methods 0.000 description 4
- 229920001817 Agar Polymers 0.000 description 3
- 241001052560 Thallis Species 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 230000003385 bacteriostatic effect Effects 0.000 description 3
- 229960002227 clindamycin Drugs 0.000 description 3
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 3
- 230000001079 digestive effect Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000007689 inspection Methods 0.000 description 3
- 238000009630 liquid culture Methods 0.000 description 3
- 238000004321 preservation Methods 0.000 description 3
- 230000000529 probiotic effect Effects 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 description 2
- 206010006326 Breath odour Diseases 0.000 description 2
- 206010019375 Helicobacter infections Diseases 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 229940046011 buccal tablet Drugs 0.000 description 2
- 239000006189 buccal tablet Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 239000003223 protective agent Substances 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 230000009044 synergistic interaction Effects 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000050 Abdominal adhesions Diseases 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 206010015137 Eructation Diseases 0.000 description 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 206010068306 Gastrointestinal bacterial infection Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000032139 Halitosis Diseases 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 206010067171 Regurgitation Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000009102 absorption Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 229960003022 amoxicillin Drugs 0.000 description 1
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
- 229940124350 antibacterial drug Drugs 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 150000001621 bismuth Chemical class 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 208000023652 chronic gastritis Diseases 0.000 description 1
- 229960002626 clarithromycin Drugs 0.000 description 1
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- -1 diamine citrate Chemical class 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 229910052564 epsomite Inorganic materials 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 235000021001 fermented dairy product Nutrition 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 208000024798 heartburn Diseases 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 1
- 229910000357 manganese(II) sulfate Inorganic materials 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 229960000282 metronidazole Drugs 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013923 monosodium glutamate Nutrition 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 229940051866 mouthwash Drugs 0.000 description 1
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
- 208000011906 peptic ulcer disease Diseases 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 108010009004 proteose-peptone Proteins 0.000 description 1
- 229940126409 proton pump inhibitor Drugs 0.000 description 1
- 239000000612 proton pump inhibitor Substances 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 229940073490 sodium glutamate Drugs 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229940034610 toothpaste Drugs 0.000 description 1
- 239000000606 toothpaste Substances 0.000 description 1
- 238000011295 triple combination therapy Methods 0.000 description 1
- 238000009777 vacuum freeze-drying Methods 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/169—Plantarum
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/175—Rhamnosus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/515—Animalis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Mycology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses an anti-helicobacter pylori instant lactic acid bacteria agent and a preparation method and application thereof, the lactic acid bacteria agent is prepared by uniformly mixing lactobacillus paracasei N1115 bacteria powder, lactobacillus plantarum N3117 bacteria powder, bifidobacterium animalis subsp lactis I797 bacteria powder, lactobacillus rhamnosus X253 bacteria powder, fructo-oligosaccharide, maltodextrin and lactitol, and can be used for preparing food, health care products or pharmaceutical compositions. The gastrointestinal fluid has good tolerance and intestinal epithelial cell adhesion, can assist in anti-helicobacter pylori treatment, restore the microecological balance in animals and relieve the adverse reactions such as oral odor and the like caused by antibiotic treatment.
Description
Technical Field
The invention belongs to the technical field of food, and relates to a lactic acid bacteria agent, in particular to an anti-helicobacter pylori instant lactic acid bacteria agent, a preparation method and an application thereof.
Background
The infection rate of helicobacter pylori in the population of China is as high as 50-80%, and the infection rate is proved to be related to certain digestive system diseases (such as gastric cancer, gastric ulcer and the like). Helicobacter pylori infection can cause bad breath and chronic gastritis of patients, symptoms are represented by halitosis, epigastric fullness, acid regurgitation, heartburn, eructation, nausea, vomiting and the like, and 15-20% of patients can have related phenomena of peptic ulcer, such as hunger pain, postprandial pain and the like, so that food intake is influenced, and the life quality of the patients is reduced.
At present, for the treatment of helicobacter pylori infection, antibiotic triple therapy is mainly used, namely, Proton Pump Inhibitor (PPI) and two antibiotics are used together or bismuth salt is used to combine the two antibiotics for treatment, and the commonly used antibiotic medicines are amoxicillin, clarithromycin, metronidazole and the like. Although the cure rate of the triple combination therapy can reach more than 90 percent, the method still has some problems: for example, antibiotics can cause gastrointestinal tract micro-ecological environment disorder, a series of digestive tract diseases such as special oral qi, gastrointestinal tract discomfort, abdominal distending pain, nausea, diarrhea, constipation and the like occur, even antibiotic-related enteritis occurs, more serious adverse reactions such as drug-resistant strains occur, and treatment repeatability is caused.
Many researches show that the probiotic preparation containing the bifidobacterium and the lactobacillus rhamnosus has remarkable curative effect when applied to an auxiliary treatment scheme of gastrointestinal bacterial infection. The probiotics can restore the micro-ecological balance in the animal body to achieve the aim of adjuvant therapy of diseases, has the functions of promoting digestion and absorption and stimulating the immune system, can partially replace antibacterial drugs, and has the advantages of safe use, no residue, no drug resistance and the like. But the selection of specific strains for resisting helicobacter pylori and the compounding among probiotics still remain problems to be solved.
Disclosure of Invention
The invention aims to provide an anti-helicobacter pylori instant lactic acid bacteria agent so as to achieve the purposes of assisting anti-helicobacter pylori treatment and relieving bad oral cavity odor and adverse reaction caused by antibiotic treatment;
another object of the present invention is to provide a preparation method of the above instant lactobacillus preparation for resisting helicobacter pylori.
The invention also aims to provide the application of the anti-helicobacter pylori instant lactobacillus preparation in preparing foods, health-care products, medicaments and medicinal compositions.
In order to achieve the purpose, the invention adopts the technical scheme that:
an anti-helicobacter pylori instant lactic acid bacteria agent comprises the following raw materials of effective components in parts by weight:
2-3 parts of lactobacillus paracasei N1115 powder, 2-3 parts of lactobacillus plantarum N3117 powder, 3-4 parts of bifidobacterium animalis subsp lactis i797 powder, 3-4 parts of lactobacillus rhamnosus X253 powder, 10-40 parts of fructo-oligosaccharide, 10-40 parts of maltodextrin and 10-20 parts of lactitol.
As a limitation, the raw materials also comprise 2-5 parts of flavor powder.
As a further limitation, the flavor powder is fruit powder.
Wherein the flavor powder comprises fruit powder, vegetable powder and the like, and has the function of seasoning and the flavor of the product is increased.
The fruit powder is instant fruit powder, is a common component in the field of food processing, and is prepared by squeezing fruit pulp to obtain fruit juice, separating the fruit juice from fruit residues, removing impurities with 3 times of 25% ethanol to obtain filtered juice, concentrating and crystallizing the filtered juice, and grinding to obtain fruit juice powder; drying and pulverizing the fruit residues to obtain fruit residue powder, mixing the fruit juice powder and the fruit residue powder, and sieving to obtain the fruit powder.
As another limitation, the bacterium contents of the lactobacillus paracasei N1115 powder and the lactobacillus plantarum N3117 powder are both more than or equal to 1x108cfu/g; the content of Bifidobacterium animalis subsp lactis i797 bacterial powder and the content of Lactobacillus rhamnosus X253 bacterial powder are both more than or equal to 0.8 × 108cfu/g。
The lactobacillus paracasei N1115 strain is preserved in China general microbiological culture collection center in 2011, 3 and 17 days, and the preservation number is as follows: CGMCC No.4691, Latin name is Lactobacillus paracasei N1115, which is disclosed for the first time in Chinese invention patent with patent number 201110357058.8;
the Lactobacillus plantarum N3117 strain is preserved in the China general microbiological culture Collection center (CGMCC) at 12/05 in 2014, with the preservation number of CGMCC NO.10133 and the Latin name of Lactobacillus plantarum N3117.
Bifidobacterium animalis lactis i797 is isolated and screened from infant or infant intestinal flora, and has been deposited in the China general microbiological culture Collection center (CGMCC NO. 18403) at 20.8.2019 with the deposit number of CGMCC, and the Latin name is Bifidobacterium animalis subsp.lactis, which is disclosed for the first time in the online patent application with the application number of 202010259210.8.
The Lactobacillus rhamnosus X253 is separated and screened from traditional fermented dairy products in Xinjiang in China, the strain is preserved in the China general microbiological culture collection center in 8-20 th month in 2019 with the preservation number of CGMCC No.18404, and the Latin article name is Lactobacillus rhamnosus which is disclosed for the first time in an online patent application document with the application number of 202010258772.0;
the invention also provides a preparation method of the anti-helicobacter pylori instant lactic acid bacteria agent, which is obtained by uniformly mixing all the raw materials.
Filling and sealing the prepared anti-helicobacter pylori instant lactic acid bacteria agent by a filling machine to obtain 2 g/strip of individually packaged lactic acid bacteria agent; after quality inspection is qualified, storing the product in a cool, dry and well-ventilated warehouse to prevent high temperature, wherein the temperature of the warehouse is not higher than 30 ℃.
As a limitation, the raw materials are obtained by crushing and sieving.
The invention also provides the application of the anti-helicobacter pylori instant lactobacillus agent in preparing food, health care products or pharmaceutical compositions. When in use, the anti-helicobacter pylori instant lactobacillus agent is added into the raw material of the prepared product for use.
The food is dairy product, modified milk powder, composite probiotics or beverage.
The dosage form of the pharmaceutical composition is capsules, tablets, pills or powder.
Due to the adoption of the technical scheme, compared with the prior art, the invention has the technical progress that:
the anti-helicobacter pylori instant lactic acid bacteria agent screens anti-helicobacter pylori specific strains according to a reasonable proportion, and mixes four lactic acid bacteria, namely lactobacillus paracasei N1115, lactobacillus plantarum N3117, bifidobacterium animalis subspecies lactis i797 and lactobacillus rhamnosus X253 according to a specific proportion, so that the synergistic interaction between the strains is fully utilized; compared with the use of a single strain, the anti-helicobacter pylori effect is obviously enhanced, the anti-helicobacter pylori treatment can be assisted, the adverse reaction caused by the antibiotic treatment can be relieved, the oral odor can be effectively improved, and the gastrointestinal fluid tolerance and the intestinal epithelial cell adhesion are good;
the anti-helicobacter pylori instant lactic acid bacteria agent has unique flavor and rich mouthfeel; the raw materials are wide in source and easy to obtain, and the preparation process steps are simple, so that the method is suitable for large-scale industrial production;
the anti-helicobacter pylori instant lactic acid bacteria agent is suitable for people infected with helicobacter pylori to eat.
Detailed Description
The present invention is further illustrated by the following specific examples, which are to be construed as merely illustrative, and not limitative of the remainder of the disclosure.
Example 1 preparation method of an anti-helicobacter pylori ready-to-eat lactic acid bacterial agent
The preparation method of the instant lactobacillus preparation for resisting helicobacter pylori in the embodiment comprises the following steps of:
1) preparation of fungal powder
I) 240g of casein peptone, 240g of beef extract, 120g of yeast extract, 480g of glucose, 120g of sodium acetate, 50g of diamine citrate, 24g of tween-80 and 50g K2HPO、3g MgSO4·7H2O、1g MnSO4·7H2And mixing O and 20kg of distilled water uniformly to prepare the MRS liquid culture medium.
Inoculating 0.2kg of lactobacillus paracasei N1115, lactobacillus plantarum N3117, bifidobacterium animalis subsp lactis i797 and lactobacillus rhamnosus X253 seed liquid into 10kg of MRS liquid culture medium (the inoculation amount of lactobacillus rhamnosus X253 or bifidobacterium animalis subsp lactis i797 is 2% of the weight of the corresponding MRS liquid culture medium), performing enrichment culture at 37 ℃ for 24h, centrifuging and separating the obtained corresponding bacterial liquids at 4 ℃ for 10min at 12000r/min respectively, removing supernatant, and washing the corresponding sediments with 10kg of physiological saline until the thalli are white to obtain corresponding thalli;
II) adding 2200g of skimmed milk powder, 1700g of trehalose, 1300g of maltodextrin, 300g of sodium glutamate and 200g of sorbitol into water, and performing constant volume to 20L to obtain a freeze-drying protective agent solution;
respectively taking lactobacillus paracasei N1115, lactobacillus plantarum N3117, bifidobacterium animalis subsp lactis i797 and lactobacillus rhamnosus X253 thalli, re-suspending in 10L of the freeze-drying protective agent solution, mixing uniformly, putting in a freeze dryer for vacuum freeze drying, grinding the obtained freeze-dried product, sieving with a 40-mesh sieve, and collecting freeze-dried powder to obtain lactobacillus paracasei N1115 bacteria powder, lactobacillus plantarum N3117 bacteria powder, bifidobacterium animalis subsp lactis i797 bacteria powder or lactobacillus rhamnosus X253 bacteria powder.
The detection proves that the bacterium contents of the lactobacillus paracasei N1115 powder and the lactobacillus plantarum N3117 powder are both more than or equal to 1 multiplied by 108cfu/g; bifidobacterium animalis subsp lactis i797 bacterial powder and mouseThe content of Lactobacillus rhamnosus X253 bacteria powder is not less than 0.8 × 108cfu/g。
2) Preparation method of fruit powder
Extracting orange pulp, squeezing to obtain juice, and separating the juice from fruit residue;
adding the juice into 25% ethanol solution with volume 3 times of the juice, shaking, mixing, filtering to obtain floccule, vacuum concentrating the filtrate, crystallizing, and grinding into powder to obtain juice powder; taking fruit residues, ventilating and drying, grinding into fruit residue powder at the temperature of 20 ℃, mixing the fruit juice powder and the fruit residue powder, sieving with a 800-mesh sieve, and mixing uniformly to obtain the fruit powder for later use.
3) Preparation of anti-helicobacter pylori instant lactic acid bacteria agent
Taking 2kg of lactobacillus paracasei N1115 powder, 2kg of lactobacillus plantarum N3117 powder, 4kg of bifidobacterium animalis subsp lactis i797 powder, 4kg of lactobacillus rhamnosus X253 powder, 20kg of fructo-oligosaccharide, 30kg of maltodextrin, 10kg of lactitol and 2kg of fruit powder, stirring and uniformly mixing, sieving by a 40-mesh sieve, filling by a filling machine, and sealing to prepare 2 g/strip of the independently packaged anti-helicobacter pylori instant lactic acid bacterial agent which is marked as J1; after quality inspection is qualified, storing the product in a cool, dry and well-ventilated warehouse to prevent high temperature, wherein the temperature of the warehouse is not higher than 30 ℃.
Through quality inspection, the content of lactobacillus paracasei N1115, lactobacillus plantarum N3117, bifidobacterium animalis subsp lactis i797 and lactobacillus rhamnosus X253 in the anti-helicobacter pylori instant lactobacillus preparation is more than or equal to 1 multiplied by 109cfu/g。
When the anti-helicobacter pylori instant lactobacillus prepared in the embodiment is applied, the lactobacillus agent J1 is added into raw materials of the prepared dairy product, meal replacement powder and pharmaceutical composition to prepare a corresponding product or be torn to eat.
Example 2-6 preparation method of an anti-helicobacter pylori Ready-to-eat lactic acid bacterium agent
Examples 2 to 6 are methods for preparing an anti-helicobacter pylori ready-to-eat lactic acid bacterial agent, which are substantially the same as in example 1 except for the difference in the amount of raw materials, and are specifically shown in table 1:
TABLE 1 List of the amounts of raw materials used in the anti-H.pylori ready-to-eat lactic acid bacteria preparation
The contents of the other portions of examples 2 to 6 are the same as those of example 1.
Comparative examples 1 'to 5': comparative examples 1 'to 5' are respectively a preparation method of an anti-helicobacter pylori instant lactic acid bacteria agent, the basic method and parameters of the preparation method are basically the same as those of example 1, and the differences are only that the types of bacteria powder in raw materials are different, specifically:
comparative example 1' no bacterial powder was added, and the prepared anti-helicobacter pylori ready-to-eat lactic acid bacterial agent was labeled D1;
comparative example 2' only lactobacillus rhamnosus X253 bacteria powder was added, and the prepared anti-helicobacter pylori ready-to-eat lactic acid bacteria agent was labeled D2;
comparative example 3' only powder of Lactobacillus paracasei N1115 was added, and the obtained anti-helicobacter pylori ready-to-eat lactic acid bacterial agent was labeled D3;
comparative example 4' only lactobacillus plantarum N3117 powder was added, and the obtained anti-helicobacter pylori ready-to-eat lactic acid bacterial agent was labeled D4;
comparative example 5' A ready-to-eat type lactic acid bacterium agent for helicobacter pylori was labeled D5, except that powder of Bifidobacterium animalis subsp.
Example 7 application of an anti-helicobacter pylori Ready-to-eat lactic acid bacterium agent
Respectively adding the anti-helicobacter pylori instant lactic acid bacteria agent J1-6 into probiotic milk tablet raw materials, sieving, uniformly mixing and pressing the raw materials to form the anti-helicobacter pylori probiotic milk tablet, and sequentially marking the probiotic milk tablet as P1-6;
the helicobacter pylori resistant instant lactic acid bacteria agents D1-5 prepared in the comparative examples 1 'to 5' respectively replace the helicobacter pylori resistant instant lactic acid bacteria agents, the agents are respectively added into raw materials of probiotic milk tablets for preparing the helicobacter pylori resistant probiotic milk tablets, the probiotic milk tablets are marked to be DP 1-5 in sequence, and the rest raw materials and the using amount are the same as those in the table 2.
The probiotic milk tablet comprises the following raw materials in a table 2:
table 2 raw material dosage summary table of probiotic milk tablets
Example 8 anti-helicobacter pylori bacteriostasis test
Preparation of fungus powder solution
Experiments are divided into 11 groups, namely a clindamycin positive control group, 4 groups of single probiotic powder groups and 6 groups of mixed probiotic powder groups which are uniformly mixed according to the proportion of the embodiment 1-6 respectively;
2g of bacterial powder (or clindamycin) of each group is respectively mixed with 8g of sterile purified water to prepare a bacterial powder solution with the concentration of 20%.
Secondly, carrying out bacteriostasis experiment by adopting an oxford cup double-layer flat plate method
(1) Cooling the 2.0% agar culture medium to about 50 ℃, pouring 10mL of the agar culture medium into a sterile plate, uniformly mixing, paving, and airing in a clean workbench;
(2) placing sterilized Oxford cup in a dish with agar, and standing for 10 min;
(3) adding 1mL of helicobacter pylori or 2mL of Gordon streptococcus into 100mL of BHI semisolid culture medium cooled to 50 ℃ and fully mixing;
(4) pouring 10mL of the BHI semisolid culture medium on a flat plate with the Oxford cup, and clamping the Oxford cup out after solidification to form an Oxford cup hole;
(5) and (3) injecting 100 mu L of 20% bacteria powder solution or clindamycin solution into the hole, carrying out anaerobic culture at 37 ℃ for 18-20 h, setting 5 groups of parallel experiments, and measuring the diameter of the inhibition zone by using a vernier caliper.
Third, experimental results
The results are shown in tables 3 and 4:
TABLE 3 bacteriostatic test group variables and result table
TABLE 4 bacteriostatic test group variables and result table
The results show that the four lactic acid bacteria of lactobacillus paracasei N1115, lactobacillus plantarum N3117, bifidobacterium animalis subsp lactis i797 and lactobacillus rhamnosus X253 are proportioned according to a specific proportion, the synergistic interaction among the strains can be fully utilized, the diameter of a bacteriostatic zone is larger compared with that of a single strain, and the effect of resisting helicobacter pylori is obviously enhanced.
Example 9 test for simulating the tolerability characteristics of gastrointestinal fluids
The four lactic acid bacteria of lactobacillus paracasei N1115, lactobacillus plantarum N3117, bifidobacterium animalis subsp lactis i797 and lactobacillus rhamnosus X253 to be detected and the four strains respectively mixed according to the proportion of the embodiment 1-6 are respectively subjected to the following operations:
activating the strain for 3 generations to obtain 10 groups of bacterial solutions, respectively taking 1mL of each group of bacterial solutions, respectively placing the 1mL of bacterial solutions in artificial gastric juice containing 9mL of filter-sterilized treatment and having a pH value of 3.0, uniformly shaking, carrying out anaerobic culture at 37 ℃, respectively sampling when the culture and the culture are started for 2 hours, and determining the viable count. Then, 1mL of the culture solution digested in artificial gastric juice at pH 3.0 for 2 hours was inoculated into 9mL of filter-sterilized artificial intestinal juice (0.9 g/100mL of Bill Salts (Difco)) at pH 8.0, and the cells were cultured at 37 ℃ and then assayed for viable cell count at 0h, 4h, and 6h, respectively. And calculating the survival rate of gastric juice or intestinal juice and the survival rate of digestive juice.
Gastric or intestinal fluid survival (%) (cfu N1/cfu N0) x 100%;
in the formula, N1: viable count of 6h after gastric juice or intestinal juice treatment, N0: treating with gastric juice or intestinal juice for 0 hr to obtain viable count;
the survival rate of digestive juice is the survival rate of the intestinal juice passing through gastric juice, and the calculation method is that the survival rate of the gastric juice is multiplied by the survival rate of the intestinal juice.
The results are shown in Table 5.
TABLE 5 simulated gastric fluid intestinal fluid tolerance results
The results show that the survival rate of the final digestive juice of the mixed strain group is obviously higher than that of the single strain group, probably because of the agglutination effect among different strains, the contact of acid and alkali is reduced, and a certain synergistic acid and alkali resistance effect is achieved, so that the probiotics are ensured to enter the intestinal tract more easily to play a role.
Example 10 intestinal epithelial cell adhesion test
In this example, the five bacterial liquids prepared in example 9 were subjected to an intestinal epithelial cell adhesion experiment to detect the adhesion of each bacterial liquid strain, and the specific method is as follows:
cultured Caco-2 cells were digested, diluted with incomplete culture of DMEM to concentration and counted (about 1X 10)5cell/mL) in CO2Incubate at 37 ℃ in an incubator. When the cells grew to a monolayer, the cells were washed 1 time with sterile PBS, and 1mL of each bacterial suspension (1X 10) was added to each group of dishes8CFU/mL), incubate for 2.5h, wash 4 times with sterile PBS. 1mL of sterilized 1% (v/v) Triton X100 was added, mixed well and left to stand for 10min to lyse the cells. The mixture was transferred to a test tube and after serial dilution, the plate colonies were counted.
Caco-2 cell adhesion bacteria count (number per cell) ═ adhesion bacteria count/cell count
TABLE 6 intestinal epithelial cell adhesion test results
The intestinal epithelial cell adhesion function is the premise that whether probiotics can be planted in human intestinal tracts for a long time or not and exert competitive occupying function with intestinal harmful bacteria, so that the strains are respectively adsorbed with different intestinal epithelial cell targets by mixing, and meanwhile, the four lactic acid bacteria have good adsorption effect, so that the adhesion number of a mixed strain group is increased, and the results in table 6 show that the four lactic acid bacteria mixed strains of lactobacillus paracasei N1115, lactobacillus plantarum N3117, bifidobacterium animalis subsp lactis I797 and lactobacillus rhamnosus X253 in reasonable proportion can better exert the effect in the intestinal tracts.
Example 11 oral malodor improving Effect test
110 subjects were recruited, 10 subjects per group, and trial experiments were performed on the helicobacter pylori resistant probiotic milk tablets prepared in example 7 in a questionnaire manner, namely DP 1-5 and P1-6, respectively, to detect the improvement effect of the probiotic milk tablets prepared by applying the method of the present invention on oral malodor.
Distributing probiotic milk tablets in a using amount within two weeks to all the subjects every two weeks, ensuring that the subjects take 1 tablet (0.8 g/tablet) three times a day, putting the tablets in the mouth for buccal administration, and keeping the tablets in the oral cavity for at least 2-3min for swallowing; the food is taken once after being eaten 30min each day in the morning, at noon and at night, and the teeth, food and mouth wash are not needed after the food is eaten for half an hour; the oral hygiene is kept according to the original habit during the eating period, and the fluorine-containing toothpaste is not used.
Weekly issue to subjects questionnaires, survey indices including:
oral odor A score (self-evaluation)
Closing the mouth for about 1 minute before filling the questionnaire every week, folding the hands into a closed bowl, simultaneously covering the nose and the mouth, then directly judging the breath and scoring the peculiar smell: 0 points indicates no peculiar smell in the oral cavity; score 1 indicates little odor; 2 points indicate that the oral odor is light; score 3 indicates oral malodor; score 4 indicates strong off-flavor; score 5 indicates an intolerable off-taste.
② oral peculiar smell B score (evaluation of others)
Counting the reaction condition of other people to self oral peculiar smell in one week, and scoring according to the reaction frequency of other people: score 0 means never; score 1 indicates rarely; score 2 indicates time; score 3 indicates frequent; a score of 4 indicates always.
Questionnaires were collected and data were collated, and the results are shown in tables 7, 8:
TABLE 7 oral malodour questionnaire results statistics Table
TABLE 8 oral malodour questionnaire results statistics table
Note: the data are expressed as means ± standard deviation; "x" indicates a significant level of data at P <0.05, "x" indicates a significant level of data at P <0.01, statistically different from prior trials; "a" and "b" indicate that there was a significant difference in the data between groups, P < 0.05.
The results show that the results of the comparison in the group show that the oral odor A score of the group containing only lactobacillus rhamnosus X253, only lactobacillus plantarum N3117 and mixed bacteria is remarkably reduced (P <0.05) in the 4 th week, the score of the group containing only lactobacillus paracasei N1115 and the score of the group containing only bifidobacterium animalis subsp. lactis i797 are reduced, but the results are not remarkably different (P >0.05) compared with the 0 th week before trial; the results of the comparison between the groups show that the oral odor A scores of the groups before trial are not significantly different (P is greater than 0.05), and the oral odor A score of the mixed bacteria group at the 4 th week is significantly lower than that of the rest groups (P is less than 0.05). The results show that after the buccal tablet is tried for four weeks, the degree of the oral odor A of a tested person group is obviously improved compared with that before the buccal tablet is tried, and the control group, the N1115 group and the i797 group are improved, but the results are not obvious; the improvement effect of the N3117, X253 and the equal proportion mixed group is obvious, and particularly, the improvement effect of the equal proportion mixed group is obviously stronger than that of other groups. The results show that X253 and N3117 have remarkable effect on improving the oral peculiar smell A and have synergistic effect in the mixing ratio group.
The results of the comparison in the group show that the oral odor B scores of the group containing only lactobacillus rhamnosus X253, only lactobacillus plantarum N3117 and mixed bacteria are all remarkably reduced (P <0.01) in week 4 compared with the scores before trial, and the oral odor B score of the control group containing no bacteria is not remarkably different (P > 0.05); the results of comparison among groups show that the oral odor B scores of the groups before trial and at week 4 have no significant difference (P is more than 0.05), but the score of the mixed bacteria group at week 4 is the lowest, and the result shows that the oral odor B degree of the mixed bacteria group subject shows a significant improvement effect compared with the degree before trial, and shows that the effect of the mixed groups with equal proportion on the oral odor inhibition is more significant compared with the effect of other groups.
In conclusion, through the specific combination of the strains, the interaction among the strains improves the capability of inhibiting the helicobacter pylori, has synergistic effect on oral odor and intestinal adhesion function, and has good improvement function on assisting anti-pyloric treatment and relieving oral odor and intestinal discomfort caused by taking antibiotics.
Although the present invention has been described in detail with reference to the above embodiments, it will be apparent to those skilled in the art that modifications may be made to the embodiments described above, or equivalents may be substituted for elements thereof. Any modification, equivalent replacement, or improvement made within the spirit and principle of the present invention should be included in the scope of the claims of the present invention.
Claims (7)
1. An anti-helicobacter pylori instant lactic acid bacteria agent is characterized in that the raw materials for preparing the effective components comprise the following components in parts by weight:
2-3 parts of lactobacillus paracasei N1115 powder, 2-3 parts of lactobacillus plantarum N3117 powder, 3-4 parts of bifidobacterium animalis subsp lactis i797 powder, 3-4 parts of lactobacillus rhamnosus X253 powder, 10-40 parts of fructo-oligosaccharide, 10-40 parts of maltodextrin and 10-20 parts of lactitol.
2. The anti-helicobacter pylori instant lactic acid bacteria agent according to claim 1, wherein the raw material further comprises 2-5 parts of flavor powder.
3. The anti-helicobacter pylori instant lactic acid bacteria agent according to claim 2, wherein the flavor powder is fruit powder.
4. The anti-helicobacter pylori ready-to-eat lactic acid bacterium agent according to any one of claims 1 to 3, wherein the bacterium contents of the lactobacillus paracasei N1115 bacterium powder and the lactobacillus plantarum N3117 bacterium powder are both equal to or more than 1x108cfu/g; the content of Bifidobacterium animalis subsp lactis i797 bacterial powder and the content of Lactobacillus rhamnosus X253 bacterial powder are both more than or equal to 0.8 × 108cfu/g。
5. A preparation method of the anti-helicobacter pylori instant lactic acid bacteria agent of any one of claims 1 to 4, characterized in that the agent is prepared by uniformly mixing all raw materials.
6. The method for preparing an anti-helicobacter pylori instant lactic acid bacteria agent according to claim 5, wherein the raw material is obtained by crushing and sieving.
7. Use of the anti-helicobacter pylori ready-to-eat lactic acid bacteria agent according to any one of claims 1 to 4 for preparing food, health products or pharmaceutical compositions.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110880879.3A CN113662192B (en) | 2021-08-02 | 2021-08-02 | Instant lactobacillus agent for resisting helicobacter pylori, preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110880879.3A CN113662192B (en) | 2021-08-02 | 2021-08-02 | Instant lactobacillus agent for resisting helicobacter pylori, preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113662192A true CN113662192A (en) | 2021-11-19 |
| CN113662192B CN113662192B (en) | 2024-07-02 |
Family
ID=78541089
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110880879.3A Active CN113662192B (en) | 2021-08-02 | 2021-08-02 | Instant lactobacillus agent for resisting helicobacter pylori, preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113662192B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116236511A (en) * | 2023-05-09 | 2023-06-09 | 北京科拓恒通生物技术股份有限公司 | Metagen composition and application thereof in preparation of helicobacter pylori inhibiting products |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108741090A (en) * | 2018-08-28 | 2018-11-06 | 安徽谷益生物科技有限公司 | A kind of compound probiotic functional food inhibiting helicobacter pylori |
| CN109480231A (en) * | 2018-11-16 | 2019-03-19 | 广州普维君健药业有限公司 | The composition of anti-helicobacter pylori and its application |
| CN110628660A (en) * | 2018-06-22 | 2019-12-31 | 景岳生物科技(中国)有限公司 | Lactobacillus composition for inhibiting gastritis caused by gastric helicobacter pylori and application thereof |
| CN111484957A (en) * | 2019-12-11 | 2020-08-04 | 石家庄君乐宝乳业有限公司 | Bifidobacterium animalis subsp lactis i797, and separation and purification method and application thereof |
| CN111956671A (en) * | 2020-07-06 | 2020-11-20 | 薛松晓 | Composite probiotics for treating helicobacter pylori infection |
| WO2021053642A1 (en) * | 2019-09-20 | 2021-03-25 | Sofar S.P.A. | Compositions based on bacterial strains and their use as anti-inflammatories |
| CN112746034A (en) * | 2020-09-14 | 2021-05-04 | 河北一然生物科技有限公司 | Lactobacillus rhamnosus LR863 and lactobacillus rhamnosus LR519 for synergistically inhibiting helicobacter pylori and application thereof |
| CN112931617A (en) * | 2021-02-22 | 2021-06-11 | 石家庄君乐宝乳业有限公司 | Mixed probiotic buccal tablet and preparation method thereof |
-
2021
- 2021-08-02 CN CN202110880879.3A patent/CN113662192B/en active Active
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110628660A (en) * | 2018-06-22 | 2019-12-31 | 景岳生物科技(中国)有限公司 | Lactobacillus composition for inhibiting gastritis caused by gastric helicobacter pylori and application thereof |
| CN108741090A (en) * | 2018-08-28 | 2018-11-06 | 安徽谷益生物科技有限公司 | A kind of compound probiotic functional food inhibiting helicobacter pylori |
| CN109480231A (en) * | 2018-11-16 | 2019-03-19 | 广州普维君健药业有限公司 | The composition of anti-helicobacter pylori and its application |
| WO2021053642A1 (en) * | 2019-09-20 | 2021-03-25 | Sofar S.P.A. | Compositions based on bacterial strains and their use as anti-inflammatories |
| CN111484957A (en) * | 2019-12-11 | 2020-08-04 | 石家庄君乐宝乳业有限公司 | Bifidobacterium animalis subsp lactis i797, and separation and purification method and application thereof |
| CN111956671A (en) * | 2020-07-06 | 2020-11-20 | 薛松晓 | Composite probiotics for treating helicobacter pylori infection |
| CN112746034A (en) * | 2020-09-14 | 2021-05-04 | 河北一然生物科技有限公司 | Lactobacillus rhamnosus LR863 and lactobacillus rhamnosus LR519 for synergistically inhibiting helicobacter pylori and application thereof |
| CN112931617A (en) * | 2021-02-22 | 2021-06-11 | 石家庄君乐宝乳业有限公司 | Mixed probiotic buccal tablet and preparation method thereof |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116236511A (en) * | 2023-05-09 | 2023-06-09 | 北京科拓恒通生物技术股份有限公司 | Metagen composition and application thereof in preparation of helicobacter pylori inhibiting products |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113662192B (en) | 2024-07-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2004267304B2 (en) | Lactic acid bacteria having mucosal immunopotentiation effect | |
| CN110179121A (en) | It is a kind of to improve the 5-linked probiotic composition of enteron aisle, compound solid beverage and its preparation method and application | |
| KR102136522B1 (en) | Lactobacillus reuteri lm1071 from breast milk having high safety and intestine adhesive property, and composition comprising the strain or its culture fluid | |
| CN111826299B (en) | Bifidobacterium lactis for relaxing bowel and application and preparation thereof | |
| CN114774313B (en) | Use of lactobacillus rhamnosus LRa05 in preparing constipation relieving product or intestinal flora regulating product | |
| CN112056399A (en) | Probiotic composition for enhancing immunity and application thereof | |
| US11376289B2 (en) | Composition and uses thereof | |
| CN110643524B (en) | Composite probiotic preparation with gastrointestinal tract mucosa protection effect and application thereof | |
| WO2022206300A1 (en) | Composition capable of facilitating defecation and use thereof | |
| JP2011505354A (en) | A composition for relieving hangover, containing Kamisuwato containing Kigushi as an active ingredient | |
| CN111528479A (en) | Probiotics and prebiotics composition for relieving atopic dermatitis function and application | |
| KR20100058823A (en) | Antiviral composition of fermented milk from lactic bacteria and its therof | |
| CN114468306B (en) | Application of bacillus coagulans BC99 in preparation of colitis relieving product or immunoregulation product | |
| CN116121154B (en) | Leuconostoc lactis and application thereof | |
| US20130309212A1 (en) | Lactobacillus salivarius and method for preparing metabolite thereof, composition of lactobacillus salivarius and metabolite thereof and use of the composition | |
| CN109315769A (en) | It is a kind of for improving the composition and preparation method thereof of human body enteral environment | |
| WO2020118576A1 (en) | Use of lactobacillus plantarum twk10 in preparation of composition for resistance to post-exercise inflammation or for reducing body fat | |
| CN115838675A (en) | Lactobacillus rhamnosus and composition and application thereof | |
| CN113662192B (en) | Instant lactobacillus agent for resisting helicobacter pylori, preparation method and application thereof | |
| JP2005013211A (en) | Lactobacillus-containing food composition | |
| CN114223728A (en) | Preterm/low birth weight infant formula containing prebiotics and probiotics | |
| CN112029676B (en) | Probiotic composition beneficial to improving immunity and application thereof | |
| CN115948296B (en) | Lactobacillus plantarum for improving musculoskeletal health and/or improving exercise capacity, and composition and application thereof | |
| CN111528486A (en) | Composition containing lactoferrin | |
| CN115844019A (en) | Probiotic capable of regulating intestinal tract and application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information | ||
| CB02 | Change of applicant information |
Address after: 050000 No. 68 stone Copper Road, Hebei, Shijiazhuang Applicant after: JUNLEBAO Dairy Group Co.,Ltd. Address before: 050000 No. 68 stone Copper Road, Hebei, Shijiazhuang Applicant before: THE SHIJIAZHUANG JUNLEBAO DAIRY Co.,Ltd. |
|
| GR01 | Patent grant |